asthma
pregnanc
health
issu
great
concern
physiolog
chang
drug
complianc
pregnanc
affect
asthma
control
vari
degre
control
level
asthma
side
effect
asthma
medic
close
relat
advers
perinat
outcom
mother
fetu
articl
provid
updat
avail
literatur
regard
allevi
aggrav
mechan
asthma
pregnanc
diagnosi
diseas
assess
systemat
manag
provid
new
guidanc
physician
obstetr
joint
doctor
health
care
practition
asthma
pregnanc
common
respiratori
diseas
burden
gradual
increas
worldwid
becom
one
common
public
health
problem
e
incid
asthma
pregnanc
increas
unit
state
women
suffer
asthma
pregnanc
britain
australia
asthma
control
level
often
chang
pregnanc
gener
believ
onethird
asthma
patient
aggrav
due
pregnanc
occur
middl
pregnanc
onethird
improv
signific
chang
observ
remain
patient
latest
multicasecontrol
studi
show
percentag
asthma
worsen
pregnanc
lower
previou
data
worsen
significantli
associ
sever
diseas
ere
also
mani
problem
control
asthma
pregnanc
studi
show
patient
poor
control
asthma
pregnanc
inhal
technolog
correct
case
patient
know
differ
asthma
reliev
control
medic
patient
receiv
written
asthma
action
plan
patient
spirometri
past
year
peak
expiratori
flow
meter
home
studi
shown
matern
asthma
increas
risk
advers
complic
fetus
mother
includ
sga
small
gestat
age
lbw
low
birth
weight
congenit
malform
cleft
lip
cleft
palat
increas
perinat
mortal
pb
prematur
birth
matern
preeclampsia
gestat
hypertens
gestat
diabet
prenat
hemorrhag
caesarean
section
urinari
tract
infect
excess
amniot
fluid
prematur
ruptur
membran
especi
patient
sever
uncontrol
asthma
pregnanc
onset
pregnanc
e
pathogenesi
asthma
remiss
aggrav
pregnanc
relat
physiolog
patholog
chang
caus
pregnanc
mainli
includ
mechan
chang
caus
uterin
enlarg
direct
indirect
effect
hormon
chang
pregnanc
increas
uteru
abdomin
pressur
diaphragm
elev
cm
subcost
angl
increas
earli
late
pregnanc
transvers
anteroposterior
diamet
thorac
increas
e
chang
partial
compens
relax
ligament
attach
rib
lead
decreas
thorac
complianc
result
total
lung
volum
decreas
frc
function
residu
capac
decreas
moreov
increas
bodi
weight
lead
larger
neck
circumfer
smaller
oropharyng
area
contribut
dyspnea
pregnanc
pregnanc
order
meet
need
matern
fetal
metabol
seri
import
chang
occur
hormon
level
includ
obviou
increas
progesteron
estrogen
cortisol
prostaglandin
differ
effect
cours
asthma
progesteron
stimul
respiratori
dynam
increas
sensit
respiratori
center
carbon
dioxid
estrogen
increas
sensit
progesteron
receptor
respiratori
center
jointli
particip
chang
respiratori
function
e
minut
ventil
increas
mainli
due
increas
tidal
volum
signific
chang
respiratori
rate
tlc
total
lung
capac
vc
vital
capac
lung
complianc
dlco
diffus
capac
remain
unchang
fvc
forc
vital
capac
forc
expiratori
volum
ratio
fvc
pefr
peak
expiratori
flow
rate
signific
chang
pregnanc
compar
nonpregn
erefor
spirometri
use
identifi
dyspnea
normal
pregnanc
reflect
chang
respiratori
diseas
addit
act
respiratori
center
progesteron
mediat
mucos
vasodil
congest
result
increas
pregnanc
rhiniti
epistaxi
incid
oropharyng
laryngopharyng
airway
contribut
attack
asthma
pregnanc
estradiol
increas
matern
innat
immun
cellor
humoralmedi
adapt
immun
low
concentr
estradiol
promot
cell
respons
cellmedi
immun
high
concentr
estradiol
enhanc
cell
respons
humor
immun
progesteron
inhibit
matern
immun
respons
chang
balanc
respons
although
cellmedi
immun
import
respiratori
viral
infect
transfer
immun
consid
import
mechan
asthma
induc
hormon
pregnanc
women
state
hypercortison
pregnanc
meanwhil
placenta
secret
crh
corticotropinreleas
hormon
acth
adrenocorticotrop
hormon
result
increas
free
cortisol
conjug
cortisol
pregnanc
e
increas
free
cortisol
mediat
increas
betaadrenoceptor
enhanc
bronchiectasi
increas
secret
prostaglandin
pregnanc
antiinflammatori
inhibit
smooth
muscl
cell
prolifer
bronchial
relax
mechan
protect
effect
incid
asthma
addit
progesteron
also
effect
chang
airway
smooth
muscl
tension
caus
bronchiectasi
ese
factor
associ
asthma
remiss
pregnanc
gener
speak
effect
mechan
biochem
chang
respiratori
system
pregnant
complex
especi
effect
variou
hormon
respiratori
center
peripher
airway
immun
system
lead
nonasthmat
pregnant
women
experienc
vari
degre
dyspnea
pregnanc
pregnant
women
asthma
import
strengthen
manag
asthma
pregnanc
avoid
matern
hypoxia
maintain
adequ
fetal
oxygen
gener
asthma
defin
histori
one
type
respiratori
symptom
wheez
short
breath
chest
tight
cough
vari
time
intens
often
appear
worsen
viral
infect
attack
night
wake
usual
trigger
exercis
laughter
allergen
cold
air
togeth
variabl
expiratori
airflow
limit
one
test
posit
includ
bronchodil
revers
test
bronchial
provoc
test
pef
variabl
confirm
variabl
expiratori
airflow
limit
compar
gener
asthma
asthma
pregnanc
similar
clinic
manifest
howev
pregnant
woman
complain
short
breath
chest
tight
must
care
diagnos
base
medic
histori
know
twothird
pregnant
women
experi
form
short
breath
chest
tight
gestat
period
physiolog
chang
pregnanc
addit
would
advis
carri
bronchial
provoc
test
prevent
matern
hypoxia
fetal
distress
assess
asthma
usual
includ
asthma
control
symptom
control
futur
risk
advers
outcom
treatment
issu
particularli
inhal
techniqu
adher
comorbid
contribut
symptom
burden
poor
qualiti
life
lung
function
feno
exhal
nitric
oxid
act
asthma
control
test
score
blood
eosinophil
count
import
tool
asthma
assess
pefr
use
monitor
lung
function
lmin
person
best
valu
requir
maintain
person
best
valu
consid
normal
rang
asthma
patient
feno
indic
airway
inflamm
studi
found
pregnant
women
asthma
feno
associ
asthma
control
adjust
treatment
asthma
pregnanc
accord
feno
reduc
acut
attack
neonat
admiss
rate
e
assess
asthma
pregnanc
collabor
effort
physician
obstetr
joint
doctor
health
care
practition
necessari
evalu
pregnant
women
also
comment
growth
develop
fetu
frequenc
assess
need
frequent
month
recommend
gina
global
initi
asthma
wholecours
manag
asthma
pregnanc
reduc
neg
effect
fluctuat
asthma
symptom
acut
exacerb
pregnant
women
fetu
e
gina
guidelin
suggest
poor
asthma
control
acut
exacerb
pregnanc
riski
take
asthma
medic
e
longterm
goal
asthma
manag
achiev
good
symptom
control
maintain
normal
activ
level
minim
risk
acut
attack
irrevers
damag
lung
function
drugrel
advers
effect
asthma
pregnanc
also
essenti
avoid
side
effect
drug
pregnant
fetus
give
birth
healthi
babi
e
principl
asthma
treatment
defin
select
appropri
treatment
base
sever
control
level
patient
written
asthma
control
plan
develop
newli
diagnos
patient
regular
followup
monitor
adjust
treatment
accord
patient
control
level
achiev
maintain
asthma
control
ough
principl
medic
asthma
pregnanc
similar
nonpregn
patient
differ
implement
stepwis
approach
gener
asthma
control
level
asthma
assess
month
use
control
medic
ose
good
asthma
control
treat
step
treatment
persist
asthma
symptom
acut
exacerb
treat
stepup
treatment
asthma
pregnanc
gina
guidelin
australian
asthma
handbook
recommend
asthma
control
level
assess
monthli
stepdown
treatment
prioriti
order
avoid
acut
exacerb
asthma
unless
pregnant
woman
drug
dosag
inappropri
addit
antiig
monoclon
antibodi
specif
immunotherapi
initi
pregnanc
current
commonli
use
safe
drug
pregnanc
includ
glucocorticoid
anticholinerg
theophyllin
leukotrien
receptor
antagonist
ltra
omalizumab
allergen
immunotherapi
ait
among
glucocorticoid
inhal
administr
predomin
inhal
glucocorticoid
ic
effect
inhibit
number
activ
inflammatori
cell
airway
moreov
significantli
reduc
side
effect
system
medic
sinc
effect
local
airway
budesonid
commonli
use
safe
ic
pregnanc
studi
base
danish
medic
registri
primipar
women
gave
birth
liveborn
singleton
found
associ
use
glucocorticoid
ic
oral
glucocorticoid
oc
earli
pregnanc
risk
oral
cleft
congenit
malform
overal
offspr
tegethoff
et
al
studi
motherchild
pair
danish
nation
birth
cohort
found
ic
asthma
treatment
pregnanc
n
budesonid
fluticason
beclomethason
unspecifi
glucocorticoid
associ
offspr
diseas
risk
categori
except
offspr
endocrin
metabol
nutrit
disord
howev
mortenet
al
indic
fraction
exhal
nitric
oxid
feno
guid
asthma
manag
pregnanc
reduc
doctordiagnos
asthma
offspr
stage
preschool
partli
mediat
alter
use
dose
ic
trial
manag
asthma
pregnanc
mani
studi
fail
clarifi
whether
use
ic
increas
risk
teratogen
clear
asthma
patient
use
ic
significantli
increas
risk
give
birth
lowweight
children
suggest
risk
poor
asthma
control
much
higher
medic
vicki
et
al
support
conclus
eir
research
suggest
placenta
play
import
role
regul
fetal
growth
produc
enzym
convert
endogen
exogen
glucocorticoid
deriv
matern
circul
inact
metabolit
consequ
activ
posit
correl
birth
weight
asthmat
patient
without
use
ic
activ
reduc
placenta
femal
fetus
may
associ
inflammatori
factor
produc
pathogenesi
asthma
use
low
moder
high
dose
ic
affect
placent
capac
metabolis
glucocorticoid
affect
birth
weight
may
relat
fact
ic
abl
increas
product
placenta
addit
uncontrol
asthma
frequent
show
associ
advers
perinat
outcom
previous
demonstr
exacerb
cohort
asthma
pregnanc
continu
use
ic
budesonid
recommend
particularli
good
safeti
profil
short
asthma
advers
effect
placenta
treatment
addit
studi
shown
low
dose
ic
patient
asthma
pregnanc
reduc
risk
acut
exacerb
readmiss
safeti
issu
highdos
ic
luci
blai
et
al
conduct
cohort
studi
pregnanc
women
asthma
found
women
use
ic
significantli
like
babi
malform
women
use
women
use
found
risk
women
use
icss
first
trimest
cohort
studi
incorpor
pregnanc
also
discov
increas
preval
lbw
pb
sga
pregnant
women
asthma
longact
laba
use
ic
dose
day
trend
increas
preval
outcom
seen
ic
dose
matern
glucocorticoidregul
system
suscept
ic
canadian
respiratori
journal
first
second
trimest
third
trimest
asthma
pregnanc
glucocorticoidregul
pathway
fetu
affect
ic
use
impli
ic
use
control
asthma
pregnanc
unlik
contribut
advers
effect
fetal
growth
develop
oc
sometim
necessari
depend
sever
asthma
keep
mind
among
oc
prednison
prednisolon
methylprednisolon
cross
placenta
low
concentr
dexamethason
betamethason
reach
fetu
higher
concentr
among
prednison
common
oc
enter
fetal
blood
circul
placenta
blood
concentr
inactiv
action
littl
impact
fetu
accumul
evid
suggest
use
oc
increas
incid
cleft
lip
palat
fetu
especi
first
trimest
pregnanc
e
incid
cleft
lip
palat
gener
popul
oral
glucocorticoidstak
pregnant
women
howev
also
studi
believ
risk
cleft
palat
uncorrel
applic
oc
pregnanc
use
oc
throughout
pregnanc
may
increas
incid
preeclampsia
preterm
birth
low
birth
weight
anim
experi
show
glucocorticoid
exposur
earli
placent
could
contribut
preeclampsia
mechan
involv
inhibit
trophoblast
prolifer
migrat
invas
epithelialmesenchym
transit
glucocorticoid
populationbas
studi
oc
also
report
increas
risk
preeclampsia
jennif
et
al
conduct
metaanalysi
paper
relat
risk
advers
outcom
neonat
acut
attack
asthma
oral
corticosteroid
asthma
sever
show
acut
attack
matern
asthma
oral
corticosteroid
use
signific
effect
low
birth
weight
preterm
deliveri
moderatetosever
asthma
pregnanc
also
associ
increas
risk
sga
low
birth
weight
infant
ere
evid
asthma
pregnanc
perceiv
higher
risk
oc
medic
use
fetu
compar
ic
treatment
may
lead
abnorm
behavior
women
pregnanc
term
risk
tradeoff
poor
asthma
control
use
oc
current
consensu
remain
risk
inadequ
treatment
higher
potenti
risk
system
glucocorticoid
suitabl
asthma
patient
level
pregnanc
quantit
inhal
atom
solut
main
administr
method
shortact
saba
includ
salbutamol
terbutalin
pirbuterol
use
reliev
medic
naepp
recommend
prefer
choic
saba
salbutamol
safeti
data
pregnant
asthma
laba
salmeterol
formoterol
control
medic
laba
similar
salbutamol
pharmacolog
toxicolog
profil
limit
data
use
pregnanc
salmeterol
might
chosen
avail
longer
report
indic
use
longact
laba
pregnanc
increas
preval
perinat
outcom
howev
current
studi
relationship
perinat
advers
outcom
still
controversi
research
find
signific
relationship
major
congenit
malform
sga
infant
exposur
theophyllin
cromolyn
corticosteroid
first
trimest
time
retrospect
cohort
studi
pregnanc
find
increas
risk
congenit
malform
saba
exposur
first
trimest
use
laba
first
trimest
significantli
associ
higher
risk
major
cardiac
malform
major
unspecifi
congenit
malform
howev
bia
due
differ
asthma
sever
chanc
consid
review
identifi
origin
studi
studi
report
use
saba
pregnanc
increas
risk
congenit
malform
one
studi
report
high
dose
saba
decreas
risk
four
studi
indic
saba
andor
laba
contribut
increas
risk
congenit
malform
one
studi
show
signific
increas
risk
laba
one
studi
show
laba
led
low
birth
weight
babi
populationbas
casemalform
control
studi
includ
registr
congenit
anomali
euromedicat
registri
find
exposur
first
trimest
inhal
increas
risk
cleft
palat
gastroschisi
also
exposur
combin
laba
ic
associ
renal
dysplasia
howev
cohort
studi
case
hypertens
disord
pregnanc
case
preeclampsiaeclampsia
laba
use
associ
increas
risk
hdp
preeclampsiaeclampsia
suggest
safeti
laba
cure
asthma
pregnanc
besid
matern
asthma
close
associ
increas
risk
offspr
autism
spectrum
disord
asd
advers
effect
associ
prenat
exposur
asthma
medic
includ
laba
gina
suggest
saba
alon
longer
recommend
therapeut
strategi
asthma
instead
gina
recommend
adult
adolesc
asthma
receiv
either
symptomdriven
mild
asthma
daili
inhal
antiinflammatori
control
treatment
reduc
risk
seriou
exacerb
control
symptom
anticholinerg
includ
shortact
muscarin
antagonist
sama
ipratropium
bromid
longact
muscarin
antagonist
lama
tiotropium
bromid
gina
guidelin
suggest
combin
formoterol
saba
could
use
treat
sever
acut
asthma
attack
previou
studi
also
demonstr
use
saba
plu
ipratropium
bromid
effect
improv
sever
acut
asthma
control
howev
still
much
controversi
whether
ipratropium
bromid
reduc
admiss
rate
patient
improv
lung
function
studi
find
patient
poor
asthma
control
appli
ic
ic
combin
laba
tiotropium
addon
therapi
improv
pulmonari
function
reduc
frequenc
exacerb
systemat
review
randomizedplacebo
control
trial
use
anticholinerg
tiotropium
amelior
asthma
control
patient
moder
symptomat
asthma
alreadi
receiv
mediumtohigh
dose
ic
icslaba
studi
use
anticholinerg
asthma
patient
pregnanc
studi
need
confirm
relationship
anticholinerg
drug
perinat
advers
outcom
lowdos
theophyllin
consid
altern
mild
persist
asthma
pregnanc
altern
adjunct
longact
bronchodil
therapi
moderatetosever
asthma
ic
alon
provid
adequ
control
patient
asthma
eophyllin
pass
placent
barrier
ere
signific
differ
theophyllin
concentr
matern
umbil
cord
serum
level
theophyllin
greater
transient
neonat
vomit
tremor
tachycardia
occur
e
blood
concentr
maintain
ml
nonpregn
asthma
patient
pregnant
women
serum
theophyllin
higher
risk
theophyllin
toxic
reaction
increas
sinc
recommend
dose
theophyllin
close
toxic
dose
plasma
urin
concentr
must
close
monitor
treatment
especi
pregnant
women
whose
liver
metabol
function
decreas
e
updat
gina
guidelin
indic
lowdos
theophyllin
serum
concentr
must
monitor
close
consid
altern
prefer
treatment
mild
persist
asthma
pregnanc
moderatetosever
asthma
pregnanc
theophyllin
may
consid
altern
adjunct
longact
bronchodil
therapi
prefer
therapi
ic
alon
provid
adequ
asthma
control
pregnanc
addit
theophyllin
use
minim
effect
fetal
growth
reduc
perinat
complic
matern
asthma
adequ
control
multicent
prospect
studi
compar
effect
ic
oral
theophyllin
asthmat
pregnant
women
two
cohort
similar
rate
asthma
exacerb
asthma
outcom
obstetr
perinat
outcom
theophyllin
group
advers
event
drug
withdraw
rate
observ
period
predict
valu
lung
function
glucocorticoid
group
present
use
controlledreleas
theophyllin
prepar
advoc
dilat
bronchu
hour
conduc
control
night
asthma
intraven
aminophyllin
mostli
use
acut
asthma
attack
teratogen
effect
found
antileukotrien
divid
two
categori
ltra
includ
zafirlukast
montelukast
pathway
inhibitor
zileuton
among
zileuton
recommend
use
pregnanc
lack
relev
research
need
monitor
liver
function
medic
ltra
alon
less
effect
compar
ic
gener
taken
combin
asthma
medic
howev
use
ltra
combin
ic
effect
laba
combin
ic
asthmat
patient
exposur
ltra
asthma
patient
pregnanc
increas
risk
major
birth
defect
observ
cohort
studi
firsttrimesterexpos
pregnanc
advers
outcom
includ
pregnanc
loss
gestat
diabet
preeclampsia
low
matern
weight
gain
preterm
deliveri
low
apgar
score
small
size
discov
cohort
studi
infant
treat
leukotrien
receptor
antagonist
pregnanc
e
ltra
recommend
patient
favor
respons
becom
pregnant
ey
altern
icss
prefer
treatment
option
mild
persist
asthmat
pregnanc
antiig
monoclon
antibodi
omalizumab
addon
therapi
treatment
nonpregn
patient
moderatetosever
persist
asthma
inadequ
control
ic
effect
prevent
exacerb
reduc
frequenc
asthmat
symptom
reduc
frequenc
emerg
room
visit
hospit
admiss
reduc
steroid
dose
prospect
observ
studi
expect
omalizumab
pregnanc
registri
includ
pregnant
women
expos
dose
omalizumab
within
week
prior
concept
time
pregnanc
collect
data
pregnant
women
time
data
cutoff
e
proport
major
congenit
anomali
prematur
low
birth
weight
sga
observ
expect
registri
consist
find
studi
asthma
popul
e
preval
major
congenit
defect
expect
higher
report
gener
popul
asthma
omalizumab
appear
increas
risk
prematur
sga
infant
beyond
seen
gener
asthma
popul
consid
possibl
anaphylaxi
therapi
initi
pregnanc
though
sometim
may
continu
alreadi
progress
addit
safeti
still
notabl
problem
name
dose
titrat
omalizumab
omalizumab
dose
accord
bodi
weight
pretreat
canadian
respiratori
journal
serum
total
ige
level
inject
subcutan
everi
week
inject
rang
mg
maximum
dose
mg
everi
week
unit
state
america
mg
european
union
european
union
elig
baselin
ige
level
iuml
countri
bodi
weight
must
kg
accordingli
patient
whose
bodi
weight
baselin
ige
level
rang
receiv
treatment
pregnant
women
asthma
matern
weight
chang
persist
short
period
time
fetu
grow
therefor
method
adjust
amount
omalizumab
accord
bodi
weight
challeng
matern
asthma
use
highdos
ic
approxim
uncontrol
asthma
patient
still
persist
airway
eosinophilia
accumul
evid
suggest
interleukin
il
contribut
airway
eosinophil
inflamm
addit
omalizumab
anoth
two
monoclon
antibodi
mepolizumab
reslizumab
also
approv
mainten
treatment
program
patient
uncontrol
persist
eosinophil
asthma
exacerb
phenotyp
mepolizumab
approv
fda
mainten
therapi
sever
asthma
patient
age
older
reduc
exacerb
approxim
patient
sever
asthma
reslizumab
also
fda
approv
mainten
therapi
sever
asthma
patient
age
older
benralizumab
anoth
human
monoclon
antibodi
select
receptor
also
approv
fda
addon
mainten
treatment
sever
asthma
patient
age
older
eosinophil
phenotyp
ere
adequ
studi
monoclon
antibodi
mepolizumab
reslizumab
benralizumab
use
pregnant
women
due
fact
monoclon
antibodi
cross
placenta
third
trimest
howev
studi
cynomolgu
monkey
harm
effect
observ
fetu
neonat
growth
month
birth
monkey
given
iv
benralizumab
everi
week
maximum
recommend
human
dose
throughout
pregnanc
collect
rare
report
use
monoclon
antibodi
asthma
pregnanc
advers
effect
matern
health
develop
offspr
ait
current
consid
treatment
etiolog
asthma
reliev
asthma
symptom
reduc
asthma
attack
regular
subcutan
inject
oral
administr
sublingu
administr
inject
oral
prepar
known
allergen
gener
asthma
patient
whose
symptom
well
control
partial
control
clearli
link
relev
allergen
valuabl
treatment
challeng
appli
ait
weigh
pro
con
order
improv
asthma
symptom
lung
function
bronchial
hyperreact
reduc
medic
requir
pregnant
women
asthma
cautiou
review
report
uterin
cramp
may
occur
anaphylaxi
also
possibl
side
effect
venom
immunotherapi
woman
wasp
venom
desensit
prematur
birth
week
pregnanc
gener
recogn
ait
initi
pregnanc
risk
anaphylaxi
unknown
benefit
appear
minim
howev
continu
patient
alreadi
receiv
allerg
vaccin
stabl
nonescal
dose
whose
symptom
appear
improv
group
pregnanc
atop
mother
receiv
immunotherapi
pregnanc
studi
retrospect
e
incid
prematur
toxemia
abort
neonat
death
congenit
malform
greater
gener
popul
suggest
ait
cautious
continu
pregnanc
without
signific
risk
either
mother
fetu
ere
still
studi
conclud
ait
sublingu
subcutan
safe
pregnanc
even
initi
first
time
pregnant
patient
retrospect
studi
includ
patient
pregnanc
receiv
subcutan
immunotherapi
pregnant
patient
pregnanc
without
receiv
immunotherapi
treatment
group
incid
similar
less
gener
popul
regard
abort
perinat
mortal
prematur
toxemia
congenit
malform
control
group
higher
incid
abort
prematur
toxemia
compar
treat
immunotherapi
addit
seven
patient
treatment
group
alreadi
pregnant
immunotherapi
initi
develop
complic
deliv
normal
prospect
studi
subject
divid
three
group
treatment
group
receiv
slit
sublingu
ait
n
either
hous
dust
mite
mixtur
five
allergen
pregnanc
receiv
sublingu
immunotherapi
first
time
pregnanc
control
group
receiv
budesonid
twice
daili
n
control
group
b
receiv
rescu
treatment
salbutamol
n
followup
six
year
incid
perinat
death
prematur
toxemia
pregnanc
less
gener
popul
incid
complic
higher
control
group
none
patient
develop
complic
pregnanc
none
reaction
slit
asthma
attack
pregnanc
defin
requir
medic
intervent
pregnanc
includ
unschedul
doctor
visit
emerg
depart
present
hospit
requir
ocss
occurr
rate
least
women
suffer
sever
attack
requir
oc
e
risk
sever
attack
patient
mild
moder
sever
asthma
respect
report
prospect
cohort
studi
women
asthma
pregnanc
attack
pregnanc
occur
mainli
late
second
trimest
mean
week
gestat
e
major
trigger
viral
infect
nonadher
ic
besid
undertreat
asthma
chang
hormon
level
also
play
role
attack
asthma
pregnanc
connect
increas
risk
advers
pregnanc
perinat
outcom
current
studi
shown
acut
attack
increas
risk
lbw
howev
relationship
acut
attack
advers
outcom
still
controversi
pb
sga
congenit
malform
neonat
death
hospit
well
rang
matern
placent
complic
preeclampsia
gestat
diabet
placenta
previa
caesarean
section
asthma
manag
earli
identif
asthma
attack
pregnanc
import
symptom
worsen
main
manifest
patient
combin
pef
monitor
attent
fetal
activ
help
judg
condit
pef
decreas
person
predict
suggest
sever
exacerb
patient
asthma
pregnanc
treat
earli
stage
asthma
attack
specif
step
medic
nonpregn
asthma
patient
asthma
symptom
poor
reliev
even
wors
hospit
time
order
avoid
hypoxia
pregnant
women
fetus
consid
follow
give
oxygen
inhal
pregnant
women
continu
monitor
oxygen
satur
fetal
heart
rate
use
saba
ic
activ
ad
oc
patient
poor
effect
even
use
intraven
hormon
soon
possibl
patient
respiratori
failur
manag
asthmat
pregnant
women
acut
attack
childbirth
inhal
bronchodil
control
symptom
patient
chronic
frequent
use
steroid
may
risk
adren
insuffici
deliveri
pressur
dose
mg
hydrocortison
everi
hour
use
prevent
adren
insuffici
deliveri
first
day
deliveri
furthermor
mother
use
saba
larg
dose
newborn
especi
prematur
babi
need
test
blood
glucos
within
hour
addit
asthma
patient
also
cautiou
use
common
measur
deliveri
drug
cervic
ripen
analges
anesthesia
oxytocin
prostaglandin
induc
labor
asthmat
fentanyl
accept
drug
reliev
pain
howev
morphin
meperidin
narcot
analgesia
like
caus
releas
histamin
bronchospasm
epidur
rather
gener
anesthesia
recommend
asthmat
need
painless
deliveri
reduc
risk
pulmonari
infect
atelectasi
intervent
equal
import
pharmacolog
treatment
mention
begin
articl
poor
drug
complianc
incorrect
use
inhal
drug
import
factor
make
asthma
difficult
control
especi
pregnant
women
given
potenti
risk
drug
mother
fetus
e
purpos
educ
improv
patient
complianc
standard
medic
accord
asthma
action
plan
master
correct
inhal
techniqu
selfmonitor
condit
trigger
asthma
patient
avoid
reduc
irrit
allergen
climat
chang
drug
sport
specif
environ
occup
tri
specif
environment
control
air
filtrat
special
bed
cover
addit
factor
avoid
infect
import
measur
reduc
asthma
attack
viral
infect
identifi
import
trigger
asthma
attack
risk
viral
infect
asthma
pregnanc
higher
nonpregn
women
prospect
cohort
studi
asthmat
pregnant
women
nonasthmat
pregnant
women
find
asthmat
pregnant
women
nonasthmat
pregnant
women
common
cold
pregnanc
incid
rate
ratio
ci
p
among
asthmat
pregnant
women
rhinoviru
detect
coronaviru
influenza
viru
b
enteroviru
onethird
patient
test
posit
respiratori
viru
pcr
associ
acut
exacerb
asthma
onethird
lost
control
asthma
asthma
patient
often
comorbid
like
allerg
rhiniti
sinus
gastroesophag
reflux
obes
chronic
obstruct
pulmonari
diseas
bronchiectasi
obstruct
sleep
apnea
syndrom
depress
anxieti
etc
especi
sever
uncontrol
asthma
pregnant
women
preval
gestat
rhiniti
gerd
overweight
obes
europ
depress
respect
sinc
comorbid
may
lead
worsen
symptom
drug
interact
even
increas
risk
perinat
advers
outcom
pregnant
women
activ
treatment
given
follow
pregnant
women
physic
structur
chang
direct
effect
hormon
chang
immun
function
induc
hormon
involv
control
asthma
onethird
asthma
patient
aggrav
due
pregnanc
minim
matern
fetal
perinat
risk
assess
patient
condit
earli
identif
new
onset
asthma
pregnanc
monitor
chang
asthma
symptom
pef
variabl
feno
fetal
activ
educ
improv
patient
complianc
standard
medic
avoid
trigger
treat
complic
activ
use
drug
therapi
stepwis
approach
need
written
asthma
control
plan
mani
studi
guidelin
support
fact
inadequ
treatment
greater
impact
mother
fetus
potenti
drug
side
effect
achiev
good
wholecours
manag
asthma
patient
pregnanc
still
requir
continu
effort
clinician
patient
canadian
respiratori
journal
conflict
interest
e
author
declar
conflict
interest
